IR News
Sep. 01, 2017Print(PDF/146KB)Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced that the following organizational realignment and Changes in the posts assumed by Executive Officers and other key positions, effective October 1, 2017:
Ⅰ. Organizational Realignment (effective October 1, 2017)
Drug Research (Division)
- Drug Research Division is renamed (in Japanese language only).
- Research Planning & Intelligence is renamed to Research Planning & Coordination.
- Research Administration is dissolved and its functions are transferred to Research Planning & Coordination and Corporate Service Center.
- Innovative Drug Discovery Laboratories and Drug Development Research Laboratories are reorganized into Pharmacology Research Unit and Chemistry Research Unit.
- Preclinical Research Laboratories is renamed to Preclinical Research Unit.
- Platform Technology Research Unit is created.
Sumitomo Dainippon Pharma will apply a "Project-based Research Management System" by appointing Project Leaders and Project Directors in the Drug Research Division, which is the highlight of this renaming/reorganizing, to strongly accelerate the drug discovery research projects.
Project Leaders are primarily responsible for advancing the drug discovery research projects they are in charge of, while the Project Directors are responsible for strategic proposal regarding conceptual ideas of new research programs and enrichment of research portfolio in Drug Research Division as a whole.
The Drug Research Division will work as one team to effectively maximize the research outcomes, advancing the drug discovery research projects and increasing the research success rate. The Project Leaders will take the initiative in such research team efforts.
Drug Development (Division)
- Project Management is renamed to Development Planning & Management.
- Development Administration is dissolved.
- Development Regulatory Affairs is created.
Ⅱ. Changes in Executive Officers
Changes in the posts assumed by Executive Officers (effective October 1, 2017)
Post as of October 1, 2017 | Current post | Name |
---|---|---|
Member, Board of Directors, Executive Officer Senior Executive Research Director, Drug Research Division Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center |
Member, Board of Directors, Executive Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Drug Research Division |
Toru Kimura |
Executive Officer Executive Research Director, Drug Research Division |
Executive Officer Executive Director, Drug Research Division |
Hideyuki Harada |
Ⅲ. Changes in Personnel (effective October 1, 2017)
Corporate Departments
Position as of October 1, 2017 | Current position | Name |
---|---|---|
Senior Strategic Officer - North America non-oncology business | Senior Strategic Officer - International business | Shinichiro Katayanagi |
Deputy Senior Director, Corporate Service Center | Senior Director, Research Administration | Masashi Yabuki |
Drug Research (Division)
Position as of October 1, 2017 | Current position | Name |
---|---|---|
Project Director, Early-phase Drug Research | Senior Director, External Innovation Development Office | Masakazu Hashimoto |
Project Director, Late-phase Drug Research | Senior Director, Innovative Drug Discovery Laboratories | Takeo Ishiyama |
Senior Director, Research Planning & Coordination | Senior Director, Research Planning & Intelligence | Setsuko Yamamoto |
Senior Director, External Innovation Development Office | Senior Director, Drug Development Research Laboratories | Isao Shimizu |
Senior Director, Pharmacology Research Unit | Director, Innovative Drug Discovery Research Management Group, Innovative Drug Discovery Laboratories | Michiko Ono |
Senior Director, Chemistry Research Unit | Director, Drug Development Chemistry Group I, Drug Development Research Laboratories | Katsunori Tsuboi |
Senior Director, Preclinical Research Unit | Senior Director, Preclinical Research Laboratories | Kiyoko Bando |
Senior Director, Platform Technology Research Unit Senior Director, Genomic Science Laboratories |
Senior Research Fellow, Molecular Pathophysiology Research | Hidetaka Nagata |
Drug Development (Division)
Position as of October 1, 2017 | Current position | Name |
---|---|---|
Senior Director, Development Planning & Management | Senior Director, Project Management | Teruya Murata |
Senior Director, Development Regulatory Affairs Director, Development RA Group, Development Regulatory Affairs |
Director, Development Regulatory Affairs Group, Clinical Research | Kenichi Otani |
Sales & Marketing (Division)
Position as of October 1, 2017 | Current position | Name |
---|---|---|
Deputy Executive Director, Sales & Marketing Division Senior Director, Sales & Marketing Management |
Senior Director, Sales & Marketing Management | Takuya Taguchi |
Senior Director, Distribution Management Director, Wholesaler Service Group, Distribution Management |
Senior Director, Distribution Management | Toshinobu Shiina |
Senior Director, Kita-Kanto Branch | Deputy Senior Director, Hospital Promotion, Kyushu Branch | Hiroshi Takaoka |
Senior Director, Yokohama Branch | Deputy Senior Director, Hospital Promotion, Tokai Branch | Yasutoshi Araki |
Deputy Senior Director, Hospital Promotion, Tokai Branch | Director, Osaka Psychiatry Group III, Hospital Promotion, Osaka Branch | Hidekatsu Kuroda |
Senior Director, Keiji-Hokuriku Branch | Deputy Senior Director, Hospital Promotion, Osaka Branch | Takayuki Sato |
Senior Director, Osaka Branch Deputy Senior Director, Hospital Promotion, Osaka Branch |
Senior Director, Osaka Branch | Masaichi Fujimoto |
Senior Director, Kyushu Branch Deputy Senior Director, Hospital Promotion, Kyushu Branch |
Senior Director, Yokohama Branch | Koji Yamazaki |